I am looking for answers pertaining to reproducibility, survival time of mice and possible representation of human cancers. Would really appreciate information on other simple but well established models for NSCLC on B6 mice (non-transgenic ones).
I do not think that a syngeneic mouse tumor model actually mimics the NSCLC "clinical situation".
You should closely collaborate with a pathologist and asking her / him her / his "diagnosis" about Lewis Lung carcinoma (providing 3-5 tumors at different growth stage). Is it actually a model of NSCLC. I have doubts about this.
Unfortunately, I think that if you want to mimic human NSCLC, it will be difficult to "escape" xenografts (as the model detailed in the attached article).
Thanks for your answer. However, my concern is that I can't go for immunocompromised mice since it would affect my primary findings. Further, transgenic mice models are beyond the scope for now. Therefore, I wanted to test my primary hypothesis using the lewis lung carcinoma model (even though it's not the best clinical representation). Also, I'm planning to ultimately correlate my findings with human samples. Do you think there is any other way out?
I perfectly understand your concerns and I do not think that there is any other way.
If I would be a reviewer of your work, I would actually appreciate in reading a section in the M&M and its related part in the Results with,
1) a brief "historical" summary about the LL carcinoma model,
2) histological microphotographs and "diagnosis" made by a pathologist (who could / should be a co-author of your article) explaining "what" is in fact the LLC model.
Then, in the Discussion, while you have discussed your date, you should add a paragraph indicating "what" is the LCC model, why you cannot use anotheer model, that you are perfectly aware of its limitation in terms of human NSCLC clinical realitty, but that this model reacts as human NSCLC to xxxx, xxxxx, xxxx and trying to cite each time "high-impact" journals.
Then, I think that any reviewer would accept your scientific honesty, and perfectly knowing that a model remains a model.
Thanks for your valuable opinion! This sure helps me a lot. I would have to justify any model I might use, because in the end, it's only a MODEL. Also, owing to your knowledge in the field, could you kindly answer another, rather immature doubt I have?
Is the lung tumour in Lewis Lung Carcinoma model (formed upon subcutaneous injection) a primary tumour? I know the major tumour would appear on the skin, but I would like to know if the tumours that appear on the lung are simply metastatic or represent primary lung tumour. Thanks for all the help. Really appreciate it!
Lung cancers in human are divided into two groups, i.e. small-cell-lung cancers (SCLCs) and non-small-cell-lung cancers (NSCLCs).
SCLCs represent 10-15% of lung cancers and respond relatively well to chemotherapy, including neuroendocrine therapy. They are not from epithelial origin. They arrise in the lungs.
NSCLCs thus represents 80-85% of lung cancers. They are of epithelial origin and originate from the lungs. They are chemoresistant and the highest killer among all cancer types.
NSCLCs kill the patients because of massive destuction of the lungs and metastases to the brain and the liver.
Thus, lung cancers, whatever the type, never originate from the skin. Inc contrast you can have "skin tumors" (melanomas) that can metastasize to the lungs.
I do not know the origin of the LLC model. I guess that it was initially chemically-induced and then it became a transplantable tumor. You can have these info from PubMed.
Depending on your research project, you can use a "lung cancer" model grafted subcutaneously in immunocompetent mice.
If you want a lung location for a cancer, you can use the B16F10 mouse pseudometastatic model (see the attached article).